Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
Novo Nordisk’s Japan unit posted a 5.4% increase in domestic sales in 2025, its president Keisuke Kotani said at a press conference on March 19, with obesity drug Wegovy (semaglutide) emerging as the main growth driver. While the company did…
To read the full story
Related Article
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
BUSINESS
- Shionogi’s Zurzuvae, Kissei’s Yselty Now Available in Japan
March 23, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…